Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
We look forward to meeting many of our great colleagues in Chicago in October!
Session Date/Times: May 5, 2024 from 1:00 PM to 2:45 PM (Sunday)
Presentation Number - Posterboard Number: 755 - B0256
Session Number: 135
Session Title: AMD: Mechanisms and preclinical studies
NOV 12 1:00 PM (T7) J. LEE; A Novel Surgical Adhesion Model for Studying Endometriosis-Induced Pain and Evaluation of Celecoxib Treatment
NOV 12 1:00 PM (VV52) S.-Y. NA; The importance of neurofilament light chain (NF-L) biomarker in 5XFAD Alzheimer’s disease and SOD1-G93A amyotrophic lateral sclerosis animal disease models
NOV 13 8:00 AM (U10) K. PARK; Phenotypic evaluation of SOD1-G93A transgenic mice as a model of amyotrophic lateral sclerosis and the potential of CMAP (compound muscle action potential) as an early biomarker
Naason Science CEO Larry Park was Interviewed by SBS Biz Pick Up! Trend Special on SBS News Channel. Interesting talk about Preclinical Research and CRO business in South Korea - check it out!
Osong, South Korea 2023-09-21
Naason Science to participate in COGNI+; an Addex Therapeutics Ltd.-led consortium to explore the effects of Addex’s MGLU2 NAM program in mild neurocognitive disorder (mNCD).
Naason Science Inc. (Republic of South Korea), a preclinical contract, and collaborative, research company announced participation in the Addex Therapeutics’ (Geneva, Switzerland) consortium that has been awarded a €4 million Eurostars grant. This program directly supports Addex’s metabotropic glutamate 2 (mGlu2) receptor-negative allosteric modulator (NAM) program for mild neurocognitive disorder (mNCD). The project, named COGNI+, has been instituted in order to deliver clinical candidates for IND-enabling studies. The consortium includes Naason Science (South Korea), BioAxis Research (Netherlands), Pharmidex Pharmaceutical Services (UK), and Stichting Radboud Universiteit (Netherlands).
For additional information please contact info@naasonscience.com
About Naason Science:
Naason Science has quickly become a global leader in contract and collaborative research aimed at preclinical drug development in a variety of therapeutic areas. Naason´s various preclinical modeling platforms are customized to suit the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a toolbox of state-of-the-art technologies that allow for rapid and effective testing of preclinical drug candidates quickly and a lower overall cost to drug discoverers.
For more information please see the announcement
Naason Science will be exhibiting at AFLAS 2023 Congress at Jeju International Convention Center (Jeju ICC) in Jeju island on September 13 to 15, 2023.
We will be located on the Third Floor booth number 26.
May 7, 2023 - Osong, Republic of South Korea; Edinburgh, United Kingdom
Naason Science Ltd. shows presence and support for those suffering from endometriosis by attending the World Congress of Endometriosis in Edinburgh, Scotland.
Women’s health and genitourinary health issues remain a largely unmet need on a global scale. Naason Science, its scientific and technical staff, along with its comprehensive preclinical drug development capabilities are committed to continued support for this community through preclinical research.
Recently in Edinburgh at the World Endometriosis Congress Naason Science attended workshops and presentations as well as chairing a session of presentations outlining some of the newer experimental drug treatments aimed at endometriosis.
Naason Science’s CEO Dr Larry Chong Park teamed up with Professor Christian Becker (Oxford University) to chair a session on potential new therapies for endometriosis. It was a great opportunity to hear the thoughts on what may be on the horizon for the treatment of endometriosis in the future. The presentations were thoroughly enjoyable and thought provoking.
While addressing the responses as well as the drug discovery community present during the sessions Dr Larry Park, Naason Science CEO said, “we are very happy to be able to receive and comment on the information provided by those presenting the data for these possible future therapies aimed at endometriosis. Despite my 25 years as a drug discoverer, I am always interested in how others see the route forward for certain technologies. It is obvious to us at Naason that the world endometriosis community is committed to finding new ways to tackle this potentially debilitating disease and this only makes Naason just as committed. Therefore, it is important that we remain in touch with developers as well as those advocating for increasing the amount of research and research funding into this disease area. The work that Naason continues to do the area of endometriosis is currently unmat5hced in the preclinical sector and we will increase this over the coming year.”
Naason science thanks all of the attendees with whom we met as well as all of those who presented their data and ideas at the WCE in Edinburgh.
Professor Christian Becker from Oxford University and Naason Science’s CEO Dr Larry Chong Park
Immediate Availability of Transgenic Cohorts for in vivo Studies:
Naason Science’s CNS modelling platform has the following lines immediately available for the study of aspects Alzheimer’s disease and associated pathologies:
Naason Science’s Parkinson’s disease modelling platform has immediate availability of aged cohorts of alpha-synuclein ( α – syn) mice immediately available for study.
Additionally, there are several cohorts of SOD1 for the study of therapies aimed at aspects of ALS and related diseases.
Please contact Naason Science at info(a)naasonscience.com
Note: These cohorts are available for contract studies at Naason Science only and are not for transfer to other facilities, laboratories or vivarium’s.
December 16, 2022 - Naason Science won the Presidential Commendation in the Entrepreneurship Division in the field of Entrepreneurship Revitalization at the '2022 Venture Startup Promotion Awards Ceremony'.
The Venture Startup Promotion Awards Ceremony, which was held on the 15th of December, is an annual event hosted by the Ministry of SMEs and Startups to discover and encourage excellent venture companies and start-ups that lead innovative growth. Awards were given to ventures, start-ups, investment, and support institutions that contributed to job creation and industrial development this year.
Article: http://www.jbnews.com/news/articleView.html?idxno=1379318
Naason Science poster sessions at SfN 2022:
While working with 14 different international institutions is rewarding in itself, our collaboration being recognized by Frontiers is a source of pride and joy.
Access the article yourself and learn more about the emerging role of translational digital biomarkers within home cage monitoring technologies in preclinical drug discovery and development!
Published 2021-07-16
PTSD is a serious condition that can lead to intense fear, anxiety and depression. Current medication is unspecific, ineffective and has a vast number of side effects (sedation, abuse potential, sexual dysfunction). As a result, many people continue to suffer from PTSD in spite of current treatment options, indicating a critical need for new treatments.
One limiting factor in the development of treatment for PTSD is the lack of valid, translational models. Naason Science has been developing models of PTSD in the rat and has initiated a development program in a larger animal - the minipig, based on a multi-faceted prolonged stress paradigm, so as to test the efficacy of new compounds.
Published 2021-03-05
Naason Science is a CNS CRO established in Korea in 2017. Naason Science was established to target the global market from the beginning, and its partners are diverse not only in Korea but also in Europe, including Germany and the Netherlands, and Japan.
The model can be used as a biochemical and histopathological model and also exhibits evoked pain signals and non evoked signals of pain, as well as anxiety and depression.
Naason Science CEO Larry Park was interviewed to 7CJB News during visit of President Moon to KBio New Drug Development Center .
Larry´s comments at 1:10 min.
Published 2019-08-10
Naason Science has recently completed validation of the models within it’s Orthopedic modelling platform. These models include models for primary and secondary (post-traumatic, congenital etc.) OA. All models can combine MRI and CT micro-CT. The models are available in a variety of species.
The models are:
▪ Surgical model for ACLT
▪ Surgical model for Meniscectomy (MMT)
▪ Collagenase Injection
▪ Sodium monoiodoacetate /MIA
▪ Crystallin alpha B KO mouse model
The models can incorporate histopathology and biochemical analysis as we all as imaging as well as 24/7 home-cage monitoring for:
▪ General locomotion
▪ Circadian Rythm
▪ Temperature
▪ Anticipatory behaviour
▪ Social distancing – anxiety & depression
▪ Climbing/rearing behaviour
▪ Gait Analysis
▪ Feeding/drinking
▪ Grooming
For more information about our Modelling Platform for Osteoarthritis please contact info@naasonscience.com.
Copyright Naason Science
Osong, South Korea, July 10, 2019 - Addex Therapeutics announced July 9 that it will lead a consortium for the development of small-molecule negative allosteric modulators (NAMs) targeting the metabotropic glutamate receptor 7 (mGlu7) as a potential treatment to reduce fear memory in post-traumatic stress disorder (PTSD). The project, named DiSARM FEAR, has been awarded a €4.85 million Eurostars grant to cover research activities performed by all participants, including Naason Science (South Korea), Endotherm (Germany), Nucro Technics (Canada) and Radboud University (Netherlands), in addition to Addex.
PTSD is a serious anxiety disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be precisely modulated, potentially resulting in higher efficacy and fewer side effects.
The project will capitalize on the significant discovery and preclinical investigations already achieved at Addex, including preclinical studies performed using ADX71743, a prototypical selective mGlu7 receptor NAM identified and characterized by Addex (Kalinichev et al. 2013. J.Pharmcol.Exp. Ther. 344, 624-636). Published and unpublished data generated with this compound in preclinical models demonstrates the central role of mGlu7 receptors in key processes involved in fear memory. The DiSARM FEAR project aims to generate novel mGlu7 NAMs ready to enter IND enabling studies within 3 years.
Naason Science’s CSO Jonathan Friedman said of the project, “Naason’s inclusion within the consortium confirms the expertise and acumen we have been building in the area of modelling neurological and psychiatric disorders over the last few years. We are delighted to be able to collaborate with Addex and the other consortium members to quickly and effectively complete the preclinical work and facilitate the IND enabled studies in an area where there is a significant global unmet clinical need”.
“This important research not only advances a potential new avenue in PTSD but could provide insight to other neurological disorders,” said Tim Dyer, CEO of Addex. “This project is another example of our strategy to leverage non-dilutive funding and a collaborative approach to maximize the value of our unique allosteric modulation discovery platform technology, potentially leading to multiple new products for our pipeline.”
About Naason Science: Naason Science is a global leader in contract and collaborative research aimed at preclinical drug development in a variety of therapeutic areas. Naason´s various preclinical modelling platforms are customized to suit the needs of drug developers. The platforms can accommodate all drug delivery routes as well as preclinical proof-of-concept for medical devices. From in vitro systems to large and small animal in vivo models Naason Science provides a toolbox of state-of-the-art technologies that allow for rapid and effective testing of preclinical drug candidates.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
© 2024 Naason Science Inc. All rights reserved.